Until you can grasp the magnitude of our opportunity, you should probably bow out of these discussions.
RAC commenced preclinical work with Zan + immunotherapies in 2021 and are yet to report on the outcomes. If these were to prove fruitless, the anthracycline synergy opportunity is already enormous. But, I suspect the reason we've heard zip is due to the IP protection strategy.
Industry news, page-2124
-
- There are more pages in this discussion • 436 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
-0.055(3.36%) |
Mkt cap ! $274.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.63 | $1.58 | $147.1K | 91.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5388 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 4042 | 1 |
View Market Depth
| Last trade - 11.55am 07/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |